口服组蛋白去乙酰化酶抑制剂与T细胞靶向免疫治疗协同保护NOD小鼠新发自身免疫性糖尿病的β细胞代谢功能并诱导稳定缓解
在NOD-huCD3ε小鼠中,口服givinostat与亚治疗剂量otelixizumab联用使80%近期糖尿病小鼠获得持久缓解,单用otelixizumab仅47%缓解;联合治疗改善代谢状态并减少胰岛炎和自身抗原特异性CD8+ T细胞反应。
要点
- givinostat与otelixizumab联用使80%近期糖尿病NOD-huCD3ε小鼠获得持久缓解。
- 单用otelixizumab仅47%小鼠获得缓解,口服givinostat单药未能逆转已建立的糖尿病。
- 联合治疗改善代谢状态,并减少胰岛炎和自身抗原特异性CD8+ T细胞反应。
核心结论
- 组蛋白去乙酰化酶抑制剂与低剂量CD3抗体协同消除原位炎症,改善胰腺β细胞存活和代谢功能,导致长期糖尿病缓解。
研究设计与样本
- 研究使用转染人CD3ε链的NOD小鼠(NOD-huCD3ε),对近期发病糖尿病小鼠给予口服givinostat、亚治疗剂量人源化CD3抗体otelixizumab(50 μg/天,5天,静脉注射)或两者联合,分析疾病缓解、代谢特征和自身反应性T细胞反应。
主要发现
- givinostat与otelixizumab联用使80%的近期糖尿病NOD-huCD3ε小鼠获得持久缓解,而单用otelixizumab仅47%小鼠获得缓解。
- 口服givinostat单药未能逆转已建立的糖尿病,但减少了原位炎症细胞因子(IL-1β、IL-6、TNF-α)的产生。
- otelixizumab与givinostat联合强烈改善NOD-huCD3ε小鼠的代谢状态,小鼠恢复了适当产生胰岛素、控制高血糖和维持葡萄糖耐量的能力。
- 联合治疗诱导的糖尿病缓解与胰岛炎和自身抗原特异性CD8+ T细胞反应的显著减少相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM/HYPOTHESIS: Combination therapy targeting the major actors involved in the immune-mediated destruction of pancreatic beta cells appears to be an indispensable approach to treat type 1 diabetes effectively. We hypothesised that the combination of an orally active pan-histone deacetylase inhibitor (HDACi: givinostat) with subtherapeutic doses of CD3 antibodies may provide ideal synergy to treat ongoing autoimmunity. METHODS: NOD mice transgenic for the human CD3ε (also known as CD3E) chain (NOD-huCD3ε) were treated for recent-onset diabetes with oral givinostat, subtherapeutic doses of humanised CD3 antibodies (otelixizumab, 50 μg/day, 5 days, i.v.) or a combination of both drugs. Disease remission, metabolic profiles and autoreactive T cell responses were analysed in treated mice. RESULTS: We demonstrated that givinostat synergised with otelixizumab to induce durable remission of diabetes in 80% of recently diabetic NOD-huCD3ε mice. Remission was obtained in only 47% of mice treated with otelixizumab alone. Oral givinostat monotherapy did not reverse established diabetes but reduced the in situ production of inflammatory cytokines (IL-1β, IL-6, TNF-α). Importantly, the otelixizumab + givinostat combination strongly improved the metabolic status of NOD-huCD3ε mice; the mice recovered the capacity to appropriately produce insulin, control hyperglycaemia and sustain glucose tolerance. Finally, diabetes remission induced by the combination therapy was associated with a significant reduction of insulitis and autoantigen-specific CD8+ T cell responses. CONCLUSIONS/INTERPRETATION: HDACi and low-dose CD3 antibodies synergised to abrogate in situ inflammation and thereby improved pancreatic beta cell survival and metabolic function leading to long-lasting diabetes remission. These results support the therapeutic potential of protocols combining these two drugs, both in clinical development, to restore self-tolerance and insulin independence in type 1 diabetes.
引用
- Besançon A, Goncalves T, Valette F, et al. Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. Diabetologia. 2017. PMID: 29030662. doi:10.1007/s00125-017-4459-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。